ABBVIE

Break Through Cancer launches phase 2 trial using revumenib and venetoclax to eliminate minimal residual disease in acute myeloid leukemia, aiming to prevent relapse and improve survival rates.

Clark’s Gustaf H. Carlson School of Chemistry and Biochemistry opened a new lab with $750,000 from the Massachusetts Life Sciences Center, enhancing research on protein interactions and disease. Students like William Luschen-Miskovsky and Emily Schaffter now benefit from streamlined processes and industry-standard equipment, preparing them for biotech careers. The lab also supports high school STEM outreach, fostering future scientists.

AbbVie, a pharmaceutical firm with strong immunology and oncology portfolios, is compared against key competitors in the Biotechnology industry. Analysis reveals AbbVie's PE ratio is low, suggesting potential undervaluation, while its high PB ratio indicates overvaluation based on book value. A low PS ratio implies undervaluation based on sales. AbbVie's high ROE, EBITDA, and gross profit highlight strong profitability and operational efficiency, but low revenue growth indicates challenges in market expansion.

AbbVie and EvolveImmune Therapeutics collaborate to develop multispecific biologics for oncology, leveraging EvolveImmune's T-cell engager platform to create novel antibody-based therapies for solid and hematologic malignancies. EvolveImmune receives $65 million upfront and is eligible for up to $1.4 billion in option fees, milestones, and royalties.

AbbVie acquires Aliada Therapeutics for $1.4B to advance ALIA-1758, an anti-pyroglutamate amyloid beta antibody for Alzheimer's. Aliada's Modular Delivery technology aims to enhance drug delivery across the blood-brain barrier, crucial for effective Alzheimer's treatment.

AbbVie to acquire Aliada Therapeutics for $1.4 billion, advancing ALIA-1758, an anti-pyroglutamate amyloid beta antibody for Alzheimer's disease, leveraging Aliada's BBB-crossing technology.

The biopharmaceutical industry saw a 2% upturn in aggregate market capitalization to $4.3 trillion in Q3 2024, driven by FDA approvals and interest rate cuts. Bristol-Myers Squibb, Gilead Sciences, Sanofi, AbbVie, and Alnylam Pharmaceuticals led with over 10% growth. Novo Nordisk and Merck faced declines due to FDA rejections and sales drops.

AbbVie to acquire Alzheimer’s biotech Aliada for $1.4B; Philips reduces sales forecast due to China market decline.

Brown Rudnick serves as day-to-day IP counsel for Aliada Therapeutics, involved in AbbVie's $1.4B acquisition of Aliada, focused on CNS disease therapies. The deal includes Aliada's lead asset, ALIA-1758, an Alzheimer's treatment antibody, and leverages Aliada's MODEL platform for R&D. Adam Schoen leads the Brown Rudnick team in this acquisition.